Cardiol Therapeutics Announces Year-End 2025 Update on Operations Initiated pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and surpassed 50% patient enrollment, with full enrollment expected in Q2 2026. Reported positive Phase II ARCHER data showing CardiolRx™ significantly reduced left ventricular mass in patients with acute myocarditis;

#CRDL Cardiol Therapeutics Announces Year-End 2025 Update on Operations

www.stocktitan.net/news/CRDL/cardiol-therap...

UK companies in the news:

#ADVT #BSRT #CKN #CRDL #FXPO #GPM #GSK #HEX #HGT #KETL #MMIT #NRR #SAA #STS

Head to Sharesify.com for news, views and analysis.

UK companies in the news:

#3IN #ABF #ADM #AUSC #AV #BMY #CABP #CGEO #CRDL #DRX #EDV #ELM #ENT #FCH #FOXT #FSFL #GFTU #GRP #HBR #HE1 #HSP #HTG #IBST #IGG #ITV #LRE #OSB #PAGE #RKT #RM #RTO #SERE #SMWH #SNR #SPI #SRP #SSIT #TFW #TW #VTU

Head to Sharesify.com for news, views and analysis.

UK companies in the news:

#BKS #CRDL #CREI #HTG #ITM #LMS #OPT #PANR #PINE #PLUS #REE #SBTX #SSIT #TRIG #TUN

Head to Sharesify.com for news, views, analysis and more.

UK companies in the news today:

#AEWU #AHT #ATG #BGO #BLND #BOOK #BRIG #CARD #CFX #CRDL #DEBS #FDM #FRAN #FRES #GMS #HSP #KOO #LABS #MAB1 #MAG #MARS #MER #MEX #MUT #NFG #NRR #OCI #PAY #PEBB #PETS #PGH #PPHE #RDT

Head to Sharesify.com for news, views and analysis.

UK companies in the news today:

#AEWU #AHT #ATG #BGO #BLND #BOOK #BRIG #CARD #CFX #CRDL #DEBS #FDM #FRAN #FRES #GMS #HSP #KOO #LABS #MAB1 #MAG #MARS #MER #MEX #MUT #NFG #NRR #OCI #PAY #PEBB #PETS #PGH #PPHE #RDT

Head to Sharesify.com for news, views and analysis.

Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million Cardiol Therapeutics (NASDAQ: CRDL) entered a bought deal private placement to issue 10,384,616 units at $1.30 per unit for gross proceeds of $13.5 million, with an underwriter option to sell up to an additional 1,038,462 units to raise up to $1.35 million. Each unit includes one common share and one-half warrant; each full warrant exercisable at $1.75 for 24 months.The offering is expected to close on or about January 23, 2026, is subject to TSX approvals and customary conditions, and the company intends to use net proceeds to advance research and clinical development and for general corporate purposes.

#CRDL Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

www.stocktitan.net/news/CRDL/cardiol-therap...

Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers actively enrolling patients. Activation of additional top-tier clinical sites in Europe and Canada underway, further accelerating enrollment momentum. Full enrollment expected in Q2 2026.

#CRDL Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

www.stocktitan.net/news/CRDL/cardiol-therap...

Should you sell your Cardiol Therapeutics stock? Leede Financial analyst Douglas Loe has cut his target on Cardiol Therapeutics

Should you sell your Cardiol Therapeutics stock? Leede Financial analyst Douglas Loe cut his target on Cardiol Therapeutics (Cardiol Therapeutics Stock Quote, Chart, News, Analysts, Financials TSX:...

#All #posts #Analysts #Life #Sciences #crdl

Origin | Interest | Match

Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040 Cardiol Therapeutics (NASDAQ: CRDL) received a U.S. Notice of Allowance for a patent titled "Cannabidiol Compositions for Use in Treating Heart Conditions", which upon issuance will protect use of CardiolRx and CRD-38 for a broad range of cardiac disorders through October 2040.The allowance expands the company's global IP portfolio alongside granted and pending patents in Europe, Japan, Canada, Australia, and China, and complements its U.S. Orphan Drug Designation for pericarditis. Management said the allowance supports late-stage programs in recurrent pericarditis and acute myocarditis and upcoming first-in-human evaluation of CRD-38. The company plans to present ARCHER topline data on November 29, 2025, and will update on Phase III MAVERIC enrollment progress.

#CRDL Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040

www.stocktitan.net/news/CRDL/cardiol-therap...

Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases Cardiol Therapeutics (NASDAQ: CRDL) announced that full Phase II ARCHER trial data for CardiolRx will be presented on November 29, 2025 at the ESC Working Group on Myocardial & Pericardial Disease meeting in Trieste, Italy. Topline results reported improvements in extracellular volume and a significant reduction in left ventricular mass after twelve weeks of blinded therapy in acute myocarditis patients with preserved LV function.The randomized, double-blind, placebo-controlled ARCHER trial enrolled 109 patients across the US, France, Brazil, and Israel. Cardiol will host a webcast and conference call on December 1, 2025 to discuss findings and next steps.

#CRDL Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

www.stocktitan.net/news/CRDL/cardiol-therap...

Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027 Cardiol Therapeutics (NASDAQ: CRDL) completed a private placement of 11.4 million units for US$11.4 million on October 21, 2025, funding operations into Q3 2027. Each unit = one common share plus one-half warrant; whole warrants exercise at US$1.35 for 24 months with an acceleration clause if VWAP > US$2.00 for five consecutive trading days. Proceeds fully fund the pivotal MAVERIC Phase III trial and advance CRD-38 through clinical development. New ARCHER trial data showing meaningful LV mass reduction will be presented at a November 2025 cardiology conference. Certain insiders participated under MI 61-101 exemptions.

#CRDL Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027

www.stocktitan.net/news/CRDL/cardiol-therap...

Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027 MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA. New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read through

#CRDL Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027

www.stocktitan.net/news/CRDL/cardiol-therap...

🚶🏿‍♂️Lackey 3 🚶🏿‍♂️‍➡️| Yugioh Remnants - Part 16 | Sky Lark

youtube.com/shorts/ArucA...

Get Early Access to videos, builds and WIPs on my ko-fi page: ko-fi.com/MrLevaux

#YugiohRemnants #RWBY #CRDL #yugiohtcg #MrLevaux #Gamedev #BlackSky #Blerd

🚶🏿‍♂️Lackey 2 🚶🏿‍♂️‍➡️| Yugioh Remnants - Part 15 | Dove Bronzewing

youtube.com/shorts/_54Mt...

Get Early Access videos, builds and WIPs on my ko-fi page: ko-fi.com/MrLevaux

#YugiohRemnants #RWBY #CRDL #yugiohtcg #MrLevaux #Gamedev #BlackSky #Blerd

🚶🏿‍♂️ Lackey 1 🚶🏿‍♂️‍➡️ | Yugioh Remnants - Part 14 | Russle Thrush

youtube.com/shorts/lvHjb...

Early Access to Videos, Builds, and WIPs on my Ko-fi page: ko-fi.com/MrLevaux

#YugiohRemnants #RWBY #CRDL #yugiohtcg #MrLevaux #Gamedev #BlackSky #Blerd

💥 Hot Head 💥 | Yu-Gi-Oh! Remnants - Part 13 | Cardin Winchester

youtube.com/shorts/JoKXI...

Early Access to Videos, Builds, and WIPs on my Ko-fi page: ko-fi.com/MrLevaux

#YugiohRemnants #RWBY #CRDL #yugiohtcg #MrLevaux #Gamedev #BlackCreators #BlackSky

Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis Cardiol Therapeutics (NASDAQ: CRDL) has announced topline results from its Phase II ARCHER trial evaluating CardiolRx™ in acute myocarditis. The trial demonstrated a notable improvement in left ventricular extracellular volume (p = 0.0538) compared to placebo after 12 weeks of treatment.The study, which enrolled 109 patients across research centers in the US, France, Brazil, and Israel, showed improvements in multiple cardiac magnetic resonance imaging endpoints, including a significant reduction in left ventricular mass. CardiolRx™ maintained a favorable safety and tolerability profile, consistent with findings from the Phase II MAvERIC trial in recurrent pericarditis.These results provide clinical proof of concept for CardiolRx™ and support advancing its development for cardiomyopathies, heart failure, and myocarditis. The findings will be submitted for presentation at an upcoming scientific meeting and publication.

#CRDL Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

www.stocktitan.net/news/CRDL/cardiol-therap...

Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis Cardiol Therapeutics (NASDAQ: CRDL) has announced the database lock for its Phase II ARCHER trial investigating CardiolRx™ in acute myocarditis patients. The trial, which enrolled over 100 patients across research centers in the United States, France, Brazil, and Israel, is a multi-national, randomized, double-blind, placebo-controlled study.The study's primary outcome measures evaluate cardiac magnetic resonance imaging parameters after 12 weeks of therapy, focusing on global longitudinal strain and extra-cellular volume. These parameters are crucial prognostic markers for myocarditis patients. Topline results are expected within two weeks of the database lock.Notably, acute myocarditis currently has no FDA-approved drug therapies. The condition results in an average seven-day hospital stay with 4-6% in-hospital mortality risk, costing approximately $110,000 per stay in the United States.

#CRDL Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

www.stocktitan.net/news/CRDL/cardiol-therap...

If the EU Stand Up to Trump, His Only Option is Chicken Out, Again If the EU Stand Up to Trump, His Only Option is Chicken Out, Again

[PODCAST] If the EU Stand Up to Trump, His Only Option is Chicken Out, Again
audioboom.com/posts/872893...

MICROCAP CO’S COVERED TODAY:
CORDEL GROUP #CRDL
CYANCONNODE HOLDINGS #CYAN
EYE SOLUTIONS #EYE
FRENKEL TOPPING #FEN
POLAREAN IMAGING #POLX
WESTMINSTER GROUP #WSG

Ex-Eli Lilly Chief Medical Officer Strengthens Cardiol Board as Critical Phase III Trial Nears Completion Former Eli Lilly CMO Dr. Timothy Garnett brings 30 years of drug development expertise to Cardiol's board. Learn how this impacts upcoming MAVERIC trial results.

#CRDL Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders

www.stocktitan.net/news/CRDL/cardiol-therap...

11 Microcap Companies Covered, Ignore 6 PODCAST: 11 Companies Covered, Ignore 6

PODCAST: 11 Microcap Companies Covered, Ignore 6
audioboom.com/posts/871894...

MACRO
US and China agree to slash tariffs as trade war eases
PM promises tougher visa rules to fix 'broken' migration system

MICRO
#CRDL #CYAN #LIKE #MWE #MYX #SNX #TAND #TGP #TIA #VEL #VLG

Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis Cardiol Therapeutics (NASDAQ: CRDL) has initiated its pivotal Phase III MAVERIC trial by enrolling the first patient at Northwestern University, evaluating CardiolRx™ for preventing recurrent pericarditis. The multi-center, randomized, double-blind, placebo-controlled trial will enroll 110 patients across the US, Canada, and Europe.The trial follows positive Phase II MAvERIC-Pilot results presented at AHA Scientific Sessions 2024, which demonstrated marked reductions in pericarditis pain, inflammation, and yearly recurrences. CardiolRx™, granted FDA Orphan Drug Designation, is an oral drug targeting the inflammasome pathway.MAVERIC will assess patients who have been treated with IL-1 blockers for at least 12 months and are scheduled to discontinue treatment. The primary endpoint is freedom from pericarditis recurrence at 24 weeks. The study is being conducted at approximately 20 clinical sites under FDA-authorized IND application.

#CRDL Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

www.stocktitan.net/news/CRDL/cardiol-therap...

Could the US / China Trade War be a Positive for other Countries? Could the US / China Trade War be a Positive for other Countries?

Could the US / China Trade War be a Positive for other Countries?
audioboom.com/posts/870253...

MACRO
China retaliates with 84% tariffs
New Universal theme park set to open in UK

MICRO
AUDIOBOOM GROUP #BOOM
CORDEL GROUP #CRDL
FLOWTECH FLUIDPOWER #FLO
SKINBIOTHERAPEUTICS #SBTX

Major Breakthrough: Cardiol's Pericarditis Drug Shows Strong Phase II Results, FDA Grants Special Status Positive Phase II data for CardiolRx in pericarditis treatment, FDA Orphan designation secured. $30.6M cash runway extends to Q3 2026. Multiple trials advancing.

#CRDL Cardiol Therapeutics Announces Year-End 2024 Update on Operations

www.stocktitan.net/news/CRDL/cardiol-therap...

Is Reeves Finally Going for Growth? Is Reeves Finally Going for Growth?

Is Reeves Finally Going for Growth?
audioboom.com/posts/864131...

MACRO
Blow to Reeves as UK borrowing unexpectedly jumps
Reeves' future instincts are for lower taxes and less regulation.
Donald Trump considering a 10% tariff on China

MICRO
#BKS #CAU #CRDL #EXR #ITX #KRM #TRC #TRT

Millionaires Leave Britain In Record Numbers & Paying Tax Elsewhere Millionaires Leave Britain In Record Numbers & Paying Tax Elsewhere

Millionaires Leave Britain In Record Numbers
audioboom.com/posts/864017...

MACRO
Millionaires leave Britain in record numbers
Home asking prices show biggest early-year rise since 2020
Working from home 'not proper work'

MICRO
#BGO #CKT #CRDL #CSSG #GTC #JNEO #PODP #SDG #VANL

AI Can’t Fix What the Budget Broke AI Can’t Fix What the Budget Broke

AI Can’t Fix What the Budget Broke
audioboom.com/posts/863618...

MACRO
PM plans to 'unleash AI' across UK to boost growth
UK CFOs set to cut hiring and slash investment following Budget
UK Inflation & GDP Data out this Week

MICRO
#CRDL #EDEN #EYE #FTC #HVO #QTX #SOS

Does this Mean the Gloom is Becoming Less Gloomy for UK Markets? Does this Mean the Gloom is Becoming Less Gloomy for tUK Markets?

Does this Mean the Gloom is Becoming Less Gloomy for UK Markets?
audioboom.com/posts/863425...

MACRO
UK investors add record $34 billion of stocks in 2024, Calastone says
Soaring UK borrowing costs are a problem for Rachel Reeves

MICRO
#ABDX #AEO #CRDL #HRN #IGP #LIKE #PROC #RFX #TPT #VCP

#CRDL Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

www.stocktitan.net/news/CRDL/cardiol-therap...